Connected Drug Delivery Devices Market by Device Type (Infusion Pumps, Inhalers, Injection Devices), Drug Type (Biologics, Biosimilars, Small Molecule), End User, Distribution Channel - Global Forecast 2025-2032
Description
The Connected Drug Delivery Devices Market was valued at USD 4.28 billion in 2024 and is projected to grow to USD 4.98 billion in 2025, with a CAGR of 18.57%, reaching USD 16.75 billion by 2032.
Introduction to the new era of connected drug delivery devices where sensors, software, and service models converge to redefine clinical care and product strategy
Connected drug delivery devices have transitioned from isolated medical implements to intelligent points of care that generate, transmit, and act on clinical data. Advances in miniaturized sensors, low-power wireless protocols, integrated analytics, and human-centered design now enable devices to support remote titration, adherence monitoring, and closed-loop therapies that were previously impractical. As a result, device manufacturers, drug developers, and care providers are rethinking product roadmaps to embed software-driven differentiation and service-based value propositions.
This evolution is occurring alongside shifts in health system priorities. Payers and providers emphasize outcomes, continuity of care, and cost-effective management of chronic conditions, and regulatory authorities are refining pathways for connected and software-enabled medical products. Consequently, commercial models increasingly combine capital sales with recurring revenue streams tied to data services, consumables, and lifecycle support. Interoperability, security, and human factors have therefore become as important as device mechanics when assessing the clinical and commercial viability of new offerings.
Looking ahead, successful stakeholders will align device engineering, clinical evidence generation, and reimbursement strategy early in development. By integrating clinical workflows and patient experience into design and by establishing robust data governance, organizations can accelerate adoption and realize the intended improvements in safety and outcomes.
Analysis of converging technological, regulatory, and commercial shifts reshaping device design, evidence generation, and global supply chain priorities
The landscape for connected drug delivery devices is experiencing several interlocking shifts that are altering competitive dynamics and product requirements. First, the rise of closed-loop and adaptive therapies is prompting deeper integration between delivery hardware and digital control systems. This trend is reinforced by progress in algorithmic safety, edge computing, and validated clinical decision support, which together enable more precise, personalized dosing.
Second, regulatory expectations are becoming more explicit about software lifecycle management, cybersecurity risk management, and post-market real-world evidence. Consequently, engineering teams must architect devices for continuous updates and traceability while ensuring strict change-control governance. Third, payer systems are signaling a willingness to reward demonstrable improvements in adherence and outcomes, which elevates evidence generation and health economics as core activities for device sponsors. In parallel, digital channels and remote care pathways increase the importance of user experience design across diverse patient populations.
Finally, supply chain resilience and component standardization are reshaping sourcing strategies, with manufacturers balancing cost, quality, and geopolitical exposure. Taken together, these shifts demand integrated roadmaps that bridge clinical, regulatory, commercial, and operational disciplines so that new connected offerings can scale safely and sustainably.
Assessment of the cumulative operational and strategic consequences of United States tariff actions in 2025 on sourcing, manufacturing, and commercial positioning
United States tariff measures enacted in 2025 impose a cumulative effect on the connected drug delivery ecosystem by increasing cost pressure on imported components and by accelerating strategic adjustments across the value chain. Manufacturers that rely on internationally sourced electronics, batteries, and specialized polymers face heightened input-cost volatility, which in turn influences contract manufacturing decisions and total delivered cost of devices. As a result, procurement teams are revisiting supplier footprints and qualification strategies to reduce exposure to tariff-driven cost swings.
In response, several manufacturers are pursuing greater localization of critical component assembly and exploring nearshoring arrangements to North American partners to shorten lead times and simplify customs compliance. At the same time, vertical integration has become more attractive for organizations seeking control over key subassemblies and intellectual property. These structural adaptations have knock-on implications for regulatory filings and quality systems; suppliers and original equipment manufacturers must collaborate earlier on design transfer and regulatory documentation to avoid delays.
Moreover, the tariffs have influenced commercial pricing strategies and contracting negotiations with health systems. Procurement leaders increasingly demand transparent total-cost-of-ownership analyses that account for logistics, service, and consumable flows. To mitigate margin compression, firms emphasize differentiation through software services, improved patient outcomes, and extended product lifecycles, which together can offset short-term component cost increases while positioning offerings as value-enhancing investments for care providers.
Key segmentation intelligence linking device archetypes, drug modalities, care settings, and distribution pathways to guide product development and commercialization choices
A granular segmentation view clarifies where clinical need and technical capability intersect to create differentiated opportunities across device classes, drug modalities, care settings, and distribution channels. When device portfolios are examined by device type, connected infusion pumps-comprising enteral pumps, insulin pumps, and PCA pumps-stand out for their demand in continuous therapy and closed-loop control applications, whereas inhalers including dry powder inhalers, metered dose inhalers, and nebulizers require focus on dose tracking and environmental robustness. Injection devices such as autoinjectors, pen injectors, safety syringes, and standard syringes demand emphasis on ergonomics and adherence support, while nasal spray formats including manual spray and nebulized spray call for precise metering and patient interface design. Transdermal options, split between matrix and reservoir patch technologies, represent a distinct set of engineering and wearability considerations for extended-release delivery.
In parallel, the interaction with drug type matters greatly. Biologics and biosimilars often require cold-chain compatibility, precise dosing, and sensitive material contacts, which influence device material selection and storage systems. Small molecule therapies may prioritize cost-efficiency and high-volume dispensing, and vaccines emphasize single-use reliability and mass distribution logistics. This alignment between drug characteristics and device features informs product development priorities.
End user segmentation also shapes requirements; ambulatory care centers, clinics, home care settings, and hospitals exhibit different staffing models, training capabilities, and procurement cycles, which in turn alter specifications for usability, connectivity, and service support. Finally, distribution channels including direct sales, hospital pharmacy, online pharmacy, and retail pharmacy determine the commercial interface, reimbursement pathways, and after-sales support expectations. Combining these dimensions yields a nuanced view of where to prioritize engineering investments, clinical validation, and channel-specific commercialization efforts.
Regional implications of adoption patterns, regulatory frameworks, and manufacturing dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific to optimize regional strategies
Regional dynamics exert powerful influence on adoption, regulatory strategy, and supply-chain design for connected drug delivery solutions. In the Americas, health systems emphasize home-based care models and remote monitoring capabilities; payer mechanisms reward documented improvements in adherence and reduced hospital utilization, encouraging pilots and scale-ups in community and home settings. Consequently, device developers prioritizing this region invest in integration with electronic health records, remote patient monitoring platforms, and payer evidence packages.
By contrast, Europe, Middle East & Africa present a mosaic of procurement practices and regulatory frameworks that require adaptable product and reimbursement strategies. Many healthcare systems retain centralized purchasing mechanisms and hospital-centric deployment models, leading suppliers to focus on interoperability with hospital IT infrastructure and to build strong health-technology assessment dossiers. Moreover, regional regulatory harmonization efforts increase the value of standardized quality and clinical evidence approaches.
In Asia-Pacific, rapid adoption of mobile health technologies and scale manufacturing capacity have created both opportunities and competitive pressures. Cost sensitivity and diverse care delivery models lead manufacturers to balance feature sets with affordability, while strategic partnerships with local distributors and contract manufacturers accelerate market entry. Across all regions, variations in digital infrastructure, data governance rules, and clinical practice norms necessitate tailored approaches to product design, regulatory submission planning, and commercial engagement.
Strategic corporate behaviors that separate resilient leaders including platform integration, cross-sector partnerships, cybersecurity emphasis, and service-centric commercialization
Leading players in the connected drug delivery space are converging on a few strategic priorities that distinguish resilient, growth-oriented organizations. First, successful companies integrate software and data capabilities with hardware roadmaps, treating analytics and services as a core part of the product life cycle rather than as add-on features. This approach enables differentiated clinical offerings, recurring revenue, and stronger customer lock-in through platform services and care pathways.
Second, companies are accelerating partnerships across the pharmaceutical, payer, and digital-health ecosystems to co-develop bundled offerings that align reimbursement incentives with measurable outcomes. These collaborations often combine device distribution with patient support programs and remote monitoring services to demonstrate value across the care continuum. Third, investment in cybersecurity, regulatory-compliant software development life cycles, and post-market surveillance mechanisms has become a competitive imperative; purchasers look for suppliers who can manage data risk and regulatory obligations across jurisdictions.
Finally, many organizations diversify their manufacturing and supplier base to enhance resilience and control costs, while some explore service-led models including device-as-a-service and subscription-based consumables. Collectively, these strategies reflect a shift from discrete product sales toward integrated solutions that deliver clinical and operational value to health systems and patients.
Actionable strategic roadmap for device sponsors to align design, supply chain resilience, cybersecurity, and payer evidence generation for rapid and scalable adoption
Industry leaders should pursue a coordinated set of actions to realize the benefits of connected drug delivery while managing technical, regulatory, and commercial risks. First, embed human factors and clinical workflow validation early in product development to ensure that connectivity features translate into measurable improvements in adherence and safety. Early clinical collaboration reduces downstream rework and strengthens payer conversations.
Second, implement robust cybersecurity and software lifecycle capabilities that allow secure over-the-air updates, vulnerability management, and regulatory traceability. Such capabilities reduce product risk and support long-term customer relationships. Third, diversify sourcing by qualifying alternate suppliers and evaluating nearshoring options for critical components to mitigate tariff and geopolitical exposures while preserving quality controls.
Fourth, develop payer-focused evidence strategies that link device-enabled data to economic outcomes and care-pathway improvements, thereby facilitating reimbursement conversations and procurement approvals. Fifth, pursue partnerships with drug developers and service providers to offer bundled solutions that address both therapeutic efficacy and adherence. Lastly, build flexible commercial models that combine direct sales with pharmacy channels and digital distribution to reach diverse care settings and patient populations efficiently.
Comprehensive mixed-methods research approach integrating stakeholder interviews, technical artifact review, regulatory analysis, and supply-chain mapping to underpin conclusions
This analysis synthesizes primary stakeholder engagement, secondary literature review, and technical artifact analysis to ensure balanced, evidence-driven findings. Primary inputs included structured interviews with clinicians, procurement leaders, regulatory specialists, engineers, and care coordinators to capture practical constraints and adoption drivers. Secondary inputs comprised regulatory guidance documents, device safety advisories, patent filings, and technology standards to contextualize capability requirements and compliance expectations.
Technical artifact analysis involved evaluation of representative device specifications, connectivity protocols, and user-interface designs to understand integration complexity and human-factors implications. Supply-chain mapping used public component-class data and manufacturing footprint information to identify concentrations and diversification opportunities. Triangulation of these sources supported robustness checks and helped identify consistent themes across stakeholders and geographies.
The methodology emphasizes transparency: assumptions, inclusion criteria for interviews, and limitations are documented in the methodology appendix. Limitations include variability in regional regulatory interpretations and evolving tariff implementations, which executives should consider when applying findings to specific product or commercial decisions.
Concluding synthesis emphasizing the imperative to integrate product, evidence, and commercial strategies to convert connected device capabilities into measurable clinical and economic value
Connected drug delivery devices occupy a pivotal position at the intersection of engineering, clinical practice, and health-system economics. Technological capabilities now enable devices to be active participants in care pathways, but realizing that potential requires coordinated action across product design, evidence generation, regulatory compliance, and commercial strategy. Tariff-driven cost pressures and regional variations in procurement and regulation add complexity, yet they also create incentives to innovate in sourcing, partnerships, and service models.
Segmentation clarity reveals where clinical need aligns with technical feasibility, and regional insight highlights how market entry and scaling strategies must be adapted to local conditions. Corporate success will hinge on integrating software and data strategies with robust cybersecurity and lifecycle management, while simultaneously developing payer-facing value propositions that demonstrate clinical and economic benefits. By following an evidence-driven, patient-centered approach and by strengthening supply-chain resilience, organizations can both mitigate near-term headwinds and unlock long-term opportunities to improve outcomes and reduce system costs.
Note: PDF & Excel + Online Access - 1 Year
Introduction to the new era of connected drug delivery devices where sensors, software, and service models converge to redefine clinical care and product strategy
Connected drug delivery devices have transitioned from isolated medical implements to intelligent points of care that generate, transmit, and act on clinical data. Advances in miniaturized sensors, low-power wireless protocols, integrated analytics, and human-centered design now enable devices to support remote titration, adherence monitoring, and closed-loop therapies that were previously impractical. As a result, device manufacturers, drug developers, and care providers are rethinking product roadmaps to embed software-driven differentiation and service-based value propositions.
This evolution is occurring alongside shifts in health system priorities. Payers and providers emphasize outcomes, continuity of care, and cost-effective management of chronic conditions, and regulatory authorities are refining pathways for connected and software-enabled medical products. Consequently, commercial models increasingly combine capital sales with recurring revenue streams tied to data services, consumables, and lifecycle support. Interoperability, security, and human factors have therefore become as important as device mechanics when assessing the clinical and commercial viability of new offerings.
Looking ahead, successful stakeholders will align device engineering, clinical evidence generation, and reimbursement strategy early in development. By integrating clinical workflows and patient experience into design and by establishing robust data governance, organizations can accelerate adoption and realize the intended improvements in safety and outcomes.
Analysis of converging technological, regulatory, and commercial shifts reshaping device design, evidence generation, and global supply chain priorities
The landscape for connected drug delivery devices is experiencing several interlocking shifts that are altering competitive dynamics and product requirements. First, the rise of closed-loop and adaptive therapies is prompting deeper integration between delivery hardware and digital control systems. This trend is reinforced by progress in algorithmic safety, edge computing, and validated clinical decision support, which together enable more precise, personalized dosing.
Second, regulatory expectations are becoming more explicit about software lifecycle management, cybersecurity risk management, and post-market real-world evidence. Consequently, engineering teams must architect devices for continuous updates and traceability while ensuring strict change-control governance. Third, payer systems are signaling a willingness to reward demonstrable improvements in adherence and outcomes, which elevates evidence generation and health economics as core activities for device sponsors. In parallel, digital channels and remote care pathways increase the importance of user experience design across diverse patient populations.
Finally, supply chain resilience and component standardization are reshaping sourcing strategies, with manufacturers balancing cost, quality, and geopolitical exposure. Taken together, these shifts demand integrated roadmaps that bridge clinical, regulatory, commercial, and operational disciplines so that new connected offerings can scale safely and sustainably.
Assessment of the cumulative operational and strategic consequences of United States tariff actions in 2025 on sourcing, manufacturing, and commercial positioning
United States tariff measures enacted in 2025 impose a cumulative effect on the connected drug delivery ecosystem by increasing cost pressure on imported components and by accelerating strategic adjustments across the value chain. Manufacturers that rely on internationally sourced electronics, batteries, and specialized polymers face heightened input-cost volatility, which in turn influences contract manufacturing decisions and total delivered cost of devices. As a result, procurement teams are revisiting supplier footprints and qualification strategies to reduce exposure to tariff-driven cost swings.
In response, several manufacturers are pursuing greater localization of critical component assembly and exploring nearshoring arrangements to North American partners to shorten lead times and simplify customs compliance. At the same time, vertical integration has become more attractive for organizations seeking control over key subassemblies and intellectual property. These structural adaptations have knock-on implications for regulatory filings and quality systems; suppliers and original equipment manufacturers must collaborate earlier on design transfer and regulatory documentation to avoid delays.
Moreover, the tariffs have influenced commercial pricing strategies and contracting negotiations with health systems. Procurement leaders increasingly demand transparent total-cost-of-ownership analyses that account for logistics, service, and consumable flows. To mitigate margin compression, firms emphasize differentiation through software services, improved patient outcomes, and extended product lifecycles, which together can offset short-term component cost increases while positioning offerings as value-enhancing investments for care providers.
Key segmentation intelligence linking device archetypes, drug modalities, care settings, and distribution pathways to guide product development and commercialization choices
A granular segmentation view clarifies where clinical need and technical capability intersect to create differentiated opportunities across device classes, drug modalities, care settings, and distribution channels. When device portfolios are examined by device type, connected infusion pumps-comprising enteral pumps, insulin pumps, and PCA pumps-stand out for their demand in continuous therapy and closed-loop control applications, whereas inhalers including dry powder inhalers, metered dose inhalers, and nebulizers require focus on dose tracking and environmental robustness. Injection devices such as autoinjectors, pen injectors, safety syringes, and standard syringes demand emphasis on ergonomics and adherence support, while nasal spray formats including manual spray and nebulized spray call for precise metering and patient interface design. Transdermal options, split between matrix and reservoir patch technologies, represent a distinct set of engineering and wearability considerations for extended-release delivery.
In parallel, the interaction with drug type matters greatly. Biologics and biosimilars often require cold-chain compatibility, precise dosing, and sensitive material contacts, which influence device material selection and storage systems. Small molecule therapies may prioritize cost-efficiency and high-volume dispensing, and vaccines emphasize single-use reliability and mass distribution logistics. This alignment between drug characteristics and device features informs product development priorities.
End user segmentation also shapes requirements; ambulatory care centers, clinics, home care settings, and hospitals exhibit different staffing models, training capabilities, and procurement cycles, which in turn alter specifications for usability, connectivity, and service support. Finally, distribution channels including direct sales, hospital pharmacy, online pharmacy, and retail pharmacy determine the commercial interface, reimbursement pathways, and after-sales support expectations. Combining these dimensions yields a nuanced view of where to prioritize engineering investments, clinical validation, and channel-specific commercialization efforts.
Regional implications of adoption patterns, regulatory frameworks, and manufacturing dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific to optimize regional strategies
Regional dynamics exert powerful influence on adoption, regulatory strategy, and supply-chain design for connected drug delivery solutions. In the Americas, health systems emphasize home-based care models and remote monitoring capabilities; payer mechanisms reward documented improvements in adherence and reduced hospital utilization, encouraging pilots and scale-ups in community and home settings. Consequently, device developers prioritizing this region invest in integration with electronic health records, remote patient monitoring platforms, and payer evidence packages.
By contrast, Europe, Middle East & Africa present a mosaic of procurement practices and regulatory frameworks that require adaptable product and reimbursement strategies. Many healthcare systems retain centralized purchasing mechanisms and hospital-centric deployment models, leading suppliers to focus on interoperability with hospital IT infrastructure and to build strong health-technology assessment dossiers. Moreover, regional regulatory harmonization efforts increase the value of standardized quality and clinical evidence approaches.
In Asia-Pacific, rapid adoption of mobile health technologies and scale manufacturing capacity have created both opportunities and competitive pressures. Cost sensitivity and diverse care delivery models lead manufacturers to balance feature sets with affordability, while strategic partnerships with local distributors and contract manufacturers accelerate market entry. Across all regions, variations in digital infrastructure, data governance rules, and clinical practice norms necessitate tailored approaches to product design, regulatory submission planning, and commercial engagement.
Strategic corporate behaviors that separate resilient leaders including platform integration, cross-sector partnerships, cybersecurity emphasis, and service-centric commercialization
Leading players in the connected drug delivery space are converging on a few strategic priorities that distinguish resilient, growth-oriented organizations. First, successful companies integrate software and data capabilities with hardware roadmaps, treating analytics and services as a core part of the product life cycle rather than as add-on features. This approach enables differentiated clinical offerings, recurring revenue, and stronger customer lock-in through platform services and care pathways.
Second, companies are accelerating partnerships across the pharmaceutical, payer, and digital-health ecosystems to co-develop bundled offerings that align reimbursement incentives with measurable outcomes. These collaborations often combine device distribution with patient support programs and remote monitoring services to demonstrate value across the care continuum. Third, investment in cybersecurity, regulatory-compliant software development life cycles, and post-market surveillance mechanisms has become a competitive imperative; purchasers look for suppliers who can manage data risk and regulatory obligations across jurisdictions.
Finally, many organizations diversify their manufacturing and supplier base to enhance resilience and control costs, while some explore service-led models including device-as-a-service and subscription-based consumables. Collectively, these strategies reflect a shift from discrete product sales toward integrated solutions that deliver clinical and operational value to health systems and patients.
Actionable strategic roadmap for device sponsors to align design, supply chain resilience, cybersecurity, and payer evidence generation for rapid and scalable adoption
Industry leaders should pursue a coordinated set of actions to realize the benefits of connected drug delivery while managing technical, regulatory, and commercial risks. First, embed human factors and clinical workflow validation early in product development to ensure that connectivity features translate into measurable improvements in adherence and safety. Early clinical collaboration reduces downstream rework and strengthens payer conversations.
Second, implement robust cybersecurity and software lifecycle capabilities that allow secure over-the-air updates, vulnerability management, and regulatory traceability. Such capabilities reduce product risk and support long-term customer relationships. Third, diversify sourcing by qualifying alternate suppliers and evaluating nearshoring options for critical components to mitigate tariff and geopolitical exposures while preserving quality controls.
Fourth, develop payer-focused evidence strategies that link device-enabled data to economic outcomes and care-pathway improvements, thereby facilitating reimbursement conversations and procurement approvals. Fifth, pursue partnerships with drug developers and service providers to offer bundled solutions that address both therapeutic efficacy and adherence. Lastly, build flexible commercial models that combine direct sales with pharmacy channels and digital distribution to reach diverse care settings and patient populations efficiently.
Comprehensive mixed-methods research approach integrating stakeholder interviews, technical artifact review, regulatory analysis, and supply-chain mapping to underpin conclusions
This analysis synthesizes primary stakeholder engagement, secondary literature review, and technical artifact analysis to ensure balanced, evidence-driven findings. Primary inputs included structured interviews with clinicians, procurement leaders, regulatory specialists, engineers, and care coordinators to capture practical constraints and adoption drivers. Secondary inputs comprised regulatory guidance documents, device safety advisories, patent filings, and technology standards to contextualize capability requirements and compliance expectations.
Technical artifact analysis involved evaluation of representative device specifications, connectivity protocols, and user-interface designs to understand integration complexity and human-factors implications. Supply-chain mapping used public component-class data and manufacturing footprint information to identify concentrations and diversification opportunities. Triangulation of these sources supported robustness checks and helped identify consistent themes across stakeholders and geographies.
The methodology emphasizes transparency: assumptions, inclusion criteria for interviews, and limitations are documented in the methodology appendix. Limitations include variability in regional regulatory interpretations and evolving tariff implementations, which executives should consider when applying findings to specific product or commercial decisions.
Concluding synthesis emphasizing the imperative to integrate product, evidence, and commercial strategies to convert connected device capabilities into measurable clinical and economic value
Connected drug delivery devices occupy a pivotal position at the intersection of engineering, clinical practice, and health-system economics. Technological capabilities now enable devices to be active participants in care pathways, but realizing that potential requires coordinated action across product design, evidence generation, regulatory compliance, and commercial strategy. Tariff-driven cost pressures and regional variations in procurement and regulation add complexity, yet they also create incentives to innovate in sourcing, partnerships, and service models.
Segmentation clarity reveals where clinical need aligns with technical feasibility, and regional insight highlights how market entry and scaling strategies must be adapted to local conditions. Corporate success will hinge on integrating software and data strategies with robust cybersecurity and lifecycle management, while simultaneously developing payer-facing value propositions that demonstrate clinical and economic benefits. By following an evidence-driven, patient-centered approach and by strengthening supply-chain resilience, organizations can both mitigate near-term headwinds and unlock long-term opportunities to improve outcomes and reduce system costs.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of AI-driven predictive algorithms into insulin pens for personalized dosage adjustments
- 5.2. Adoption of real-time wireless monitoring platforms for chemotherapy infusion adherence tracking
- 5.3. Implementation of Bluetooth-enabled smart inhalers for remote patient respiratory data collection
- 5.4. Development of NFC based medication authentication features to prevent counterfeit injectable drugs
- 5.5. Expansion of cloud-based analytics dashboards for clinicians monitoring patient drug delivery metrics
- 5.6. Emergence of smartphone app ecosystems enabling two-way communication with implantable drug pumps
- 5.7. Integration of blockchain ledgers into connected drug delivery to enhance data security and traceability
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Connected Drug Delivery Devices Market, by Device Type
- 8.1. Infusion Pumps
- 8.1.1. Enteral Pumps
- 8.1.2. Insulin Pumps
- 8.1.3. PCA Pumps
- 8.2. Inhalers
- 8.2.1. Dry Powder Inhalers
- 8.2.2. Metered Dose Inhalers
- 8.2.3. Nebulizers
- 8.3. Injection Devices
- 8.3.1. Autoinjectors
- 8.3.2. Pen Injectors
- 8.3.3. Safety Syringes
- 8.3.4. Standard Syringes
- 8.4. Nasal Spray
- 8.4.1. Manual Spray
- 8.4.2. Nebulized Spray
- 8.5. Transdermal Patch
- 8.5.1. Matrix Patch
- 8.5.2. Reservoir Patch
- 9. Connected Drug Delivery Devices Market, by Drug Type
- 9.1. Biologics
- 9.2. Biosimilars
- 9.3. Small Molecule
- 9.4. Vaccines
- 10. Connected Drug Delivery Devices Market, by End User
- 10.1. Ambulatory Care Centers
- 10.2. Clinics
- 10.3. Home Care
- 10.4. Hospitals
- 11. Connected Drug Delivery Devices Market, by Distribution Channel
- 11.1. Online
- 11.2. Offline
- 12. Connected Drug Delivery Devices Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Connected Drug Delivery Devices Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Connected Drug Delivery Devices Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Adherium Limited
- 15.3.2. Becton, Dickinson, and Company
- 15.3.3. Novo Nordisk A/S
- 15.3.4. Cognita Labs LLC
- 15.3.5. AptarGroup, Inc.
- 15.3.6. Abbott Laboratories
- 15.3.7. Eli Lilly and Company
- 15.3.8. Findair Sp. z o. o.
- 15.3.9. Sulzer Ltd.
- 15.3.10. Presspart Verwaltungs-GmbH
- 15.3.11. OPKO Health, Inc.
- 15.3.12. Merck KGaA
- 15.3.13. Medtronic PLC
- 15.3.14. Novartis AG
- 15.3.15. Molex LLC
- 15.3.16. ResMed Inc.
- 15.3.17. Otsuka America, Inc.
- 15.3.18. F. Hoffmann-La Roche AG
- 15.3.19. Gerresheimer AG
- 15.3.20. SHL Medical AG
- 15.3.21. Teva Pharmaceutical Industries Ltd.
- 15.3.22. Viatris Inc.
- 15.3.23. West Pharmaceutical Services, Inc.
- 15.3.24. Ypsomed Holding
- 15.3.25. Zimmer Biomet Holdings, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
